CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT
Go back to CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT| (NASDAQ: CRVO) | Delayed: 2.41 -0.02 (0.82%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.43 | 52 Week High | $ | |||
| Open | $2.47 | 52 Week Low | $ | |||
| Day High | $2.49 | P/E | N/A | |||
| Day Low | $2.41 | EPS | $ | |||
| Volume | 109,104 | |||||
